Published online Sep 24, 2021. doi: 10.5306/wjco.v12.i9.712
Peer-review started: March 5, 2021
First decision: May 4, 2021
Revised: June 16, 2021
Accepted: August 3, 2021
Article in press: August 3, 2021
Published online: September 24, 2021
Processing time: 196 Days and 3.7 Hours
Immunotherapy is now commonly prescribed to cancer patients, but autoimmune-related adverse events are considerable. For severe, life-threatening side effects, cessation of therapy seems unavoidable, let alone intensive medical care required for patching up the adverse events. Even without serious adverse events, the response rates are too low and various combinatory regimens have been tried. However, toxicities are also added on, unless the adjuvant agents have remarkably few side effects. Actually, micronutrients are usually taken by a majority of cancer patients as nutritional support or to boost the immune function, let alone hoping to counteract treatment side effects. Recent studies have shown that combinations of micronutrients exert pleiotropic effects in controlling tumor growth and metastasis by modulating the tumor microenvironment, enhancing gut microbiota immune functions, and providing adjunct nutritional support to micronutrient deficient cancer patients. A higher than recommended dietary allowance micronutrient dose is proposed to reduce the toxic free radicals generated as a result of immunotherapy and tumor metabolism. This is not only helpful for managing treatment side effects but also enhancing treatment efficacy. As micronutrient supplementation is also useful to improve patients’ quality of life, prolong survival, and sustain compliance to immunotherapy, further investigations are mandatory.
Core Tip: Micronutrients in combination may enhance immunotherapy efficacy by immunomodulation and minimizing immune-related adverse events, improve acquired immune response through modification of the tumor microenvironment, enhance gut-microbiota immune functions, boost immune-nutrition function, and improve patient outcome.